Clinical Trial Update: Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil [Phase 2]

View source ↗

Summary

Phase 2 study evaluating PF-05212377 versus placebo in Alzheimer's disease patients with neuropsychiatric symptoms on donepezil was terminated; results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PF-05212377

Snippet

Sponsor: Pfizer | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED | Results posted: 2017-03-20